Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 16/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243074 | 0.91 | SCD (0.66) | SCDALDH1A1LMNAMAPK1BLM | |
| SCHEMBL14047612 | 0.90 | SCD (0.64) | SCDALDH1A1LMNAMAPK1BLM | |
| SCHEMBL245376 | 0.90 | SCD (0.77) | SCD | |
| SCHEMBL244461 | 0.87 | SCD (0.78) | SCDALDH1A1LMNAMAPK1BLM | |
| SCHEMBL242780 | 0.81 | PPARA (0.52) | SCD | |
| SCHEMBL244832 | 0.81 | SCD (0.64) | SCDALDH1A1LMNAMAPK1BLM | |
| SCHEMBL244425 | 0.78 | PPARA (0.49) | SCDALDH1A1LMNANPSR1 | |
| SCHEMBL245328 | 0.76 | SCD (1.00) | SCD | |
| SCHEMBL243920 | 0.76 | SCD (0.76) | SCDLMNA | |
| SCHEMBL243446 | 0.75 | SCD (1.00) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | claimed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885ALDH1A1 433/4885LMNA 2703/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885ALDH1A1 451/4885LMNA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.